Zacks.com on MSN7h
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback